Time to Use Peripheral Norepinephrine in the Operating Room.
W Brenton French, William B Rothstein, Michael J Scott
https://pubmed.ncbi.nlm.nih.gov/33886514/Actively Recruiting
Led by University of Texas Southwestern Medical Center · Updated on 2026-01-20
200
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are evaluating two different mixtures of propofol and etomidate anesthesia used during endoscopic procedures to determine which ratio provides more stable heart and lung function and fewer side effects. This phase 3, randomized, double-blind trial compares an admixture of propofol and etomidate at 25%75% P2E7 versus 75%25% P7E2 in adult patients undergoing these procedures. The study aims to provide clear guidance on anesthesia use in older patients or those with chronic conditions needing endoscopy. Participants receive one of two anesthesia mixtures administered during their endoscopic procedure at the Clements University Hospital endoscopy lab. Both mixtures are prepared fresh and blinded so neither patients nor clinicians know the exact ratio. Propofol and etomidate are FDA-approved drugs combined in varying ratios to assess which maintains better cardiovascular stability while minimizing adverse effects. This trial runs over an estimated 6 to 12 months. During the study, researchers monitor heart pressure, oxygen levels, use of blood pressure medications, and adverse events like nausea or emergency responses. Assessments include clinician, endoscopist, and patient evaluations of anesthesia quality. Data on recovery times and medication doses are also collected. Safety is closely followed during and after the procedure, with outcomes measured up to 30 days post-anesthesia to evaluate cardiac events and side effects.
CONDITIONS
Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)
C
Christopher Choi
K
Kapil Anand
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Texas Southwestern Medical Center
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Admixture of propofol and etomidate at 75%/25% ratio (P7E2) | Admixture of propofol and etomidate at 25%/75% ratio (P2E7) |
|---|---|---|
| what_it_is | A trial-administered admixture composed of propofol (75%) and etomidate (25%) by volume, used as the primary anesthetic agent for endoscopic procedures. | A trial-administered admixture composed of propofol (25%) and etomidate (75%) by volume, used as the primary anesthetic agent for endoscopic procedures. |
| role_in_trial | Serves as one of two randomized investigational arms to assess clinical outcomes of different propofol/etomidate admixture ratios. | Serves as one of two randomized investigational arms to assess clinical outcomes of different propofol/etomidate admixture ratios. |
| primary_use | Employed as the principal anesthetic during endoscopic procedures to provide sedation and maintain patient stability. | Employed as the principal anesthetic during endoscopic procedures to provide sedation and maintain patient stability. |
| how_it_is_given_or_performed | Delivered intravenously as an admixture under double-blind randomized trial conditions during endoscopic procedures. | Delivered intravenously as an admixture under double-blind randomized trial conditions during endoscopic procedures. |
| evidence_status | There is ongoing investigation of propofol/etomidate admixture approaches; published studies suggest that combining propofol and etomidate for sedation may reduce adverse events compared to propofol monotherapy. Evidence on specific admixture ratios for hemodynamic stability and safety remains limited. | There is ongoing investigation of propofol/etomidate admixture approaches; published studies suggest that combining propofol and etomidate for sedation may reduce adverse events compared to propofol monotherapy. Evidence on specific admixture ratios for hemodynamic stability and safety remains limited. |
| important_limitations | Evidence for specific propofol/etomidate admixture ratios is still emerging, and published studies have mostly focused on broader combinations rather than the exact ratios used in this trial. Outcomes in hemodynamic stability, safety, and patient recovery may depend on admixture ratio and population, so findings from single-center studies may be limited in generalizability. | Evidence for specific propofol/etomidate admixture ratios is still emerging, and published studies have mostly focused on broader combinations rather than the exact ratios used in this trial. Outcomes in hemodynamic stability, safety, and patient recovery may depend on admixture ratio and population, so findings from single-center studies may be limited in generalizability. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single procedure day
Participants receive anesthesia with a blinded admixture of propofol and etomidate at varying ratios during their endoscopic procedures to compare hemodynamic stability and side effect profiles.
1 visit (in-person) on procedure day
Duration - 30 days
Participants are monitored for 30 days after the procedure to assess safety outcomes including adverse events and recovery quality.
Follow-up assessments within 30 days post-procedure
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
W Brenton French, William B Rothstein, Michael J Scott
https://pubmed.ncbi.nlm.nih.gov/33886514/Shruti Goradia, Arwa Abu Sardaneh, Sujita W Narayan...
https://pubmed.ncbi.nlm.nih.gov/33220576/S Saravanan, M Kocarev, R C Wilson...
https://pubmed.ncbi.nlm.nih.gov/16311286/Lingyuan Chen, Xueyan Liang, Xinmei Tan...
https://pubmed.ncbi.nlm.nih.gov/31096522/M Mohta, M Dubey, R K Malhotra...
https://pubmed.ncbi.nlm.nih.gov/30685301/Lina Hao, Xibei Hu, Bingqing Zhu...
https://pubmed.ncbi.nlm.nih.gov/33157963/Sang Won Yoon, Geun Joo Choi, Oh Haeng Lee...
https://pubmed.ncbi.nlm.nih.gov/29526045/University of Texas Southwestern Medical Center
Lead Sponsor